Luo He-San, Xu Hong-Yao, Du Ze-Sen, Li Xu-Yuan, Wu Sheng-Xi, Huang He-Cheng, Lin Lian-Xing
Department of Radiation Oncology, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, China.
Department of Surgical Oncology, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, China.
Front Oncol. 2020 Apr 15;10:430. doi: 10.3389/fonc.2020.00430. eCollection 2020.
This present study aimed to explore the prognostic value of pretreatment neutrophil and lactate dehydrogenase (LDH) and to develop a prognostic risk scoring model to predict prognosis in esophageal squamous cell cancer (ESCC) patients treated with definitive radiotherapy. Retrospectively collected data of patients who received definitive radiotherapy for ESCC at Shantou Central Hospital between January 2009 and December 2015 were included for the analysis. The association between the level of LDH and neutrophil and clinicopathological characteristics were analyzed. We performed univariate and multivariate analyses to identify the prognostic predictors for patients with ESCC. Based on the results, we also developed a prognostic risk scoring model and assessed its predictive ability in the subgroups. A total of 567 patients who received definitive radiotherapy for ESCC were included in the present study. The optimal cutoff values were 4.5 × 10/L, 3.25, and 220 U/L for neutrophil, neutrophil-to-lymphocyte ratio (NLR), and LDH, respectively. A high level of LDH was significantly associated with advanced N stage ( = 0.031), and neutrophil count was significantly associated with gender ( = 0.001), T stage ( < 0.001), N stage ( = 0.019), clinical stage ( < 0.001), and NLR ( < 0.001). Multivariate survival analysis identified gender ( = 0.006), T stage ( < 0.001), N stage ( = 0.008), treatment modality ( < 0.001), LDH level ( = 0.012), and neutrophil count ( = 0.038) as independent prognostic factors for overall survival. Furthermore, a new prognostic risk scoring (PRS) model based on six prognostic factors was developed, in which the patients were divided into three groups with distinct prognosis (χ2 = 67.94, < 0.0001). Elevated baseline LDH level and neutrophil count predicted poor prognosis for ESCC patients treated with definitive radiotherapy. A PRS model comprised of LDH, neutrophil count, and other prognostic factors would help identify the patients who would benefit the most from definitive radiotherapy.
本研究旨在探讨治疗前中性粒细胞和乳酸脱氢酶(LDH)的预后价值,并建立一个预后风险评分模型,以预测接受根治性放疗的食管鳞状细胞癌(ESCC)患者的预后。纳入了2009年1月至2015年12月在汕头市中心医院接受ESCC根治性放疗患者的回顾性收集数据进行分析。分析了LDH水平和中性粒细胞水平与临床病理特征之间的关联。我们进行了单因素和多因素分析,以确定ESCC患者的预后预测因素。基于结果,我们还建立了一个预后风险评分模型,并评估了其在亚组中的预测能力。本研究共纳入567例接受ESCC根治性放疗的患者。中性粒细胞、中性粒细胞与淋巴细胞比值(NLR)和LDH的最佳截断值分别为4.5×10⁹/L、3.25和220 U/L。LDH高水平与晚期N分期显著相关(P = 0.031),中性粒细胞计数与性别(P = 0.001)、T分期(P < 0.001)、N分期(P = 0.019)、临床分期(P < 0.001)和NLR(P < 0.001)显著相关。多因素生存分析确定性别(P = 0.006)、T分期(P < 0.001)、N分期(P = 0.008)、治疗方式(P < 0.001)、LDH水平(P = 0.012)和中性粒细胞计数(P = 0.038)为总生存的独立预后因素。此外,基于六个预后因素建立了一个新的预后风险评分(PRS)模型,并将患者分为三组,预后明显不同(χ² = 67.94,P < 0.0001)。基线LDH水平升高和中性粒细胞计数升高预示着接受根治性放疗的ESCC患者预后不良。由LDH、中性粒细胞计数和其他预后因素组成的PRS模型将有助于识别从根治性放疗中获益最大的患者。